Pandemic Response Assessment

In the face of the COVID-19 pandemic, biopharmaceutical companies had to react quickly to develop and implement what were frequently large scale crisis response initiatives. As organizations prepare to move into the next phase, charting a path to recovery, now is the time to assess the changes that were implemented and refine business continuity plans to ensure regulatory compliance, patient safety, and organizational preparedness now and into the future.